PORTLAND, Ore. - Selective publication in reporting results of antidepressant trials exaggerates the effectiveness of the drugs, according to a report in the January 17 issue of the New England Journal of Medicine. The reportís primary author is Erick Turner, M.D., assistant professor of psychiatry, physiology and phamacology at Oregon Health & Science University (OHSU) and Medical Director of the Portland Veterans Affairs Medical Centerís Mood Disorders Program.
Turner and his colleagues examined reviews from the Food and Drug Administration (FDA) for trials of 12 widely prescribed antidepressant drugs approved between 1981 and 2004, involving 12,564 patients. They also conducted a systematic literature search to identify whether results of these studies had been published in medical journals. For trials that had been published, they compared the published version of the results with the FDA version of the results.
Whether and how the studies were published depended on how they turned out, Turnerís team found. According to the published literature, nearly all studies conducted (94 percent) had positive treatment results, but FDA data showed that in fact only about half (51 percent) of the studies were positive. Positive studies, with one exception, were all published. Most studies (33 out of 36) that were not positive either were not published or were published as if they were positive, in conflict with the FDA conclusions. These 33 studies involved 5,212 patients.
ďSelective publication can lead doctors and patients to believe drugs are more effective than they really are, which can influence prescribing decisions, said Turner. He also cautioned that the surprisingly large number of negative studies does not mean that antidepressants are ineffective. His team found that each drug, when all its studies were combined using a statistical technique called meta-analysis, was superior to treatment with a placebo (sugar pill). On the other hand, this analysis also showed that each drug, based on the FDA data, was less effective than it would appear from the published literature.
Turner said that he and his colleagues donít know whether the bias resulted from a failure of authors and sponsors to submit manuscripts, from decisions by journal editors and reviewers not to publish, or both. ďRegardless, doctors and patients must have access to evidence that is complete and unbiased when they are weighing the risks and benefits of treatment,Ē he emphasized.
Turnerís co-authors include Annette Matthews, M.D., Eftihia Linardatos, B.S., Robert Tell, L.C.S.W., and Robert Rosenthal, Ph.D. Turner has been a clinical researcher in the intramural program of the National Institutes of Healthís National Institute of Mental Health and has authored approximately 35 publications in peer reviewed journals. He served as a clinical reviewer of psychotropic drugs for three years at the FDA.
Oregon Health & Science University is the stateís only health and research university, and Oregonís only academic health center. OHSU is Portland's largest employer and the fourth largest in Oregon (excluding government), with 12,400 employees. OHSU's size contributes to its ability to provide many services and community support activities not found anywhere else in the state. It serves patients from every corner of the state, and is a conduit for learning for more than 3,400 students and trainees. OHSU is the source of more than 200 community outreach programs that bring health and education services to every county in the state. As a leader in research, OHSU earned $307 million in research funding in fiscal year 2007. OHSU serves as a catalyst for the region's bioscience industry and is an incubator of discovery, averaging one new breakthrough or innovation every three days, with more than 4,100 research projects currently under way. OHSU disclosed 132 inventions in 2007 alone, and OHSU research resulted in 33 new spinoff companies since 2000, most of which are based in Oregon.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.